Company / Cost of Revenue
Abbott Laboratories Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$19.3B
FY2025
5-year range
$13.2B / $19.3B
FY2021-FY2025
Trend
+3.3%
vs FY2024
Sector context
#9 of 113
Health Care
What the data says
Among 113 Health Care companies, Abbott Laboratories is in the bottom 8% for cost of revenue. Cost of Revenue has increased for 5 consecutive years, from $12.7B in FY2020 to $19.3B in FY2025.
Based on SEC 10-K filings.
$19.3B in FY2025 with a 5-year CAGR of +8.7%. Top quartile in the Health Care sector.
Increased from $18.5B to $19.3B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +8.8%
- 5-Year CAGR
- +8.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 113This company $19.3B Sector average $11.3B
▼
+71.0% above sector average
Key checks
Key Insights
- Abbott Laboratories's cost of revenue has grown for 5 consecutive years.
- 5-year CAGR of +8.7%, indicating consistent growth.
- In FY2025, cost of revenue increased 3.3% year-over-year.
- Ranks #9 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.3B | +3.3% |
| FY2024 | $18.7B | +0.9% |
| FY2023 | $18.5B | +23.6% |
| FY2022 | $15.0B | +13.4% |
| FY2021 | $13.2B | +4.1% |
| FY2020 | $12.7B | -4.0% |
| FY2019 | $13.2B | +45.5% |
| FY2018 | $9.1B | +4.0% |
| FY2017 | $8.7B | -5.1% |
| FY2016 | $9.2B | +0.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026